Participants
ideation, bipolar disorder, depressive, MDD, primary psychotic disorder
RHEUMATOID ARTHRITIS, DISORDER, INFLAMMATORY BOWEL DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, INFLAMMATORY DISORDER
Inclusion criteria were as follows: men and women aged 18 to 75 years; a diagnosis of MDD and a major depressive episode confirmed by the Structured Clinical Interview for Exclusion criteria were as follows: a primary psychotic disorder or bipolar disorder; history of intolerance to statins or presence of any contraindication to statins; currently taking a statin; presence of any unstable physical condition or neurological problem; presence of an autoimmune or inflammatory disorder (eg, systemic lupus erythematosus, rheumatoid arthritis, or inflammatory bowel disease); alcohol or substance use disorder within the preceding 6 months; active suicidal ideation; pregnant or breastfeeding; serum low-density lipoprotein cholesterol (LDL-C) level of less than 80 mg/dL (to convert to milligrams per deciliter, multiply by 0.0259) at baseline; and elevated aspartate transaminase, alanine transaminase, lactate dehydrogenase, or creatine phosphokinase level at baseline.During the 12-week trial, participants were required to continue to take a stable dose of the antidepressant they were currently taking and not to start taking a new antidepressant or engaging in a new psychosocial intervention. However, those who were already engaged in a psychosocial intervention at the screening stage were permitted to continue it.